Diabetes & Obesity Series
Subscribe to RSS feed of this series
Dr. David Orloff
Executive Director of Regulatory Affairs
Medpace
Dr. Orloff discusses the current and potential future regulatory issues for obesity and diabetes drugs, how FDA and industry is moving toward levels of safety for these drug classes.
Others in the Series
Associations and Societies
Clinical Trials
Articles, Multimedia
Associations and Societies
Clinical Trials